港股震荡回调，资金涌入这个ETF

Core Viewpoint - The Hong Kong stock market opened lower on July 31, but innovative drug concept stocks rose, with the Hong Kong Stock Connect Technology ETF (513860) experiencing a slight pullback after a cumulative increase of over 7% since July and nearly 40% year-to-date [1] Group 1: Market Performance - As of 10:00 AM, notable stocks included Meitu, which rose over 6%, and several others like Dongfang Zhenxuan and Kelun-Bio, which increased by over 4% [1] - The Hong Kong Stock Connect Technology ETF (513860) has seen a net inflow of 1.3 billion yuan yesterday and a total of 7.4 billion yuan over the past 20 days, indicating accelerated capital allocation [1] Group 2: Institutional Research - By July 28, 620 listed companies had received institutional research in July, with nearly 80% of these companies achieving positive returns [1] - The pharmaceutical and biotechnology sector had 66 companies receiving institutional research, highlighting opportunities in innovative drugs and devices [1] Group 3: Investment Outlook - According to Everbright Securities, the overall profitability of the Hong Kong stock market is relatively strong, with low valuations in sectors like the internet, new consumption, and innovative drugs, suggesting high long-term investment value [1] - The Hang Seng Index has recently surpassed previous highs, indicating minimal resistance to further increases, supported by ongoing domestic growth policies [1] Group 4: ETF Details - The Hong Kong Stock Connect Technology ETF (513860) closely tracks the CSI Hong Kong Stock Connect Technology RMB Index, with the top ten weighted stocks accounting for 66.97% as of July 30, 2025 [1] - The Hong Kong Stock Connect Technology Index has risen nearly 45% year-to-date, outperforming the Hang Seng Technology Index, which has increased by 24% [1]